AstraZeneca (AZN) closed at $96.34 on the latest trading day, experiencing a 1.94% increase, in contrast to the S&P 500, which fell by 0.53%. The stock has risen 3.46% over the past month, while the Medical sector gained only 0.09%.
AstraZeneca is set to report its earnings on February 10, 2026, with an anticipated EPS of $1.09 and projected revenue of $15.76 billion—representing increases of 3.81% and 5.81% year-over-year, respectively. For the fiscal year, earnings are estimated at $4.59 per share, with total revenue projected at $58.73 billion, marking a change of +11.68% in earnings and no change in revenue from the previous year.
The company’s Forward P/E ratio stands at 18.33, lower than the industry average of 20.82, and its PEG ratio is currently at 1.56. AstraZeneca holds a Zacks Rank of #3 (Hold), reflecting recent upward revisions in analysts’ estimates, which often correlate with potential stock performance.
